Safra Pays $2 Billion Dividend to Its Owners Ahead of Tax Hike

(Bloomberg) — Banco Safra SA paid 11 billion reais ($2 billion) in dividends and interest to the owners of its parent company in 2025, ahead of higher taxes that will kick in this year.

Of the total, which was the highest since at least 2016, 60% came from profits from previous years retained in the bank’s equity, according to the lender’s balance sheet. The figure was more than seven times the 2024 payment and more than twice as big as last year’s profit of 4.4 billion reais.

Many companies in Brazil paid record dividends last year to beat the change in taxes. Investors previously paid no income tax on dividends, while interest over capital distributed to shareholders was assessed at 15%. Starting this year, dividends over 50,000 reais are taxed at 10% and interest over capital at 17.5%.

Itau Unibanco Holding SA had profits of 46.9 billion reais last year, and its dividend and interest over capital paid was 48.3 billion reais.

Safra didn’t respond to messages seeking comment.

Dividends paid by São Paulo-based Banco Safra in recent decades have helped boost the fortunes of a banking and wealth-management clan spanning Brazil, the US and Switzerland. Vicky Safra, 73, heads the family with a fortune of about $27.3 billion, according to the Bloomberg Billionaires Index.

Born in Greece to a family that relocated to Brazil in the 1950s, Vicky is the widow of Joseph Safra, one of the heirs to a banking empire started in the mid-19th century in Aleppo, Syria. Joseph’s predecessors started the business funding camel trade caravans during the Ottoman Empire.

After his death in 2020, Vicky and their four children took control of the family’s most prized assets, including Basel, Switzerland-based J. Safra Sarasin, currently with nearly $288 billion in assets under management.

Jacob J. Safra, the eldest son, is the chairman of J. Safra Sarasin, which recently purchased a majority stake in the Danish online trading and investment firm Saxo Bank A/S.

Last year Joseph and Vicky’s only daughter, Esther Safra Dayan, sold a stake in her family’s business to Jacob and younger brother David, who’s based in Brazil. That happened after a years-long legal dispute incited by another sibling, Alberto, over the estate of their father.

In the agreement, Alberto said he would divest his interests in J. Safra Group and pursue his business interests through his own Sao Paulo-based investment firm, ASA.

The family’s real estate portfolio includes the Gherkin skyscraper in London and New York’s 660 Madison Ave.

Latest

Explained: Why stock markets are rising even as crude oil remains above $100

Benchmark indices rallied in early trade on Monday despite crude oil remaining elevated above $100. The move reflected bargain buying and global AI-led optimism

Sun Pharma’s biggest-ever bet: Why markets cheered the Organon mega deal

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive pr

Cohance Lifesciences hits 20% upper circuit: Why the stock rising today?

Cohance Lifesciences jumped 20% after appointing former Cipla CEO Umang Vohra. Investors are betting his leadership can accelerate growth and transform the comp

Decoding the Sun Pharma $11.75 billion deal: Why the pharma stock jumped 7% today?

The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest

Paytm shares tumble 6% today: Is this dip a buying chance for investors?

Paytm shares fell 6% today. Is this panic-driven weakness, or a smart chance for investors to buy into the fintech stock at lower levels now?

Topics

Explained: Why stock markets are rising even as crude oil remains above $100

Benchmark indices rallied in early trade on Monday despite crude oil remaining elevated above $100. The move reflected bargain buying and global AI-led optimism

Sun Pharma’s biggest-ever bet: Why markets cheered the Organon mega deal

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive pr

Watch out Apple and Samsung, OpenAI is making AI smartphone with agentic capabilities

OpenAI is reportedly working with MediaTek and Qualcomm on smartphone processors, aiming to build an AI-first device powered by agent-led experiences.

ICSE, ISC board results to be out this week? Here’s what CISCE official has to say

The Council for the Indian School Certificate Examinations (CISCE) will declare the much-awaited ICSE Class 10 and ISC Class 12 Results 2026 shortly. Officials

Sam Altman says Codex is causing major FOMO so he changing his sleep schedule

Sam Altman says GPT-5.5 in Codex is so good he’s cutting sleep. He has said due to AI he has switched to polyphasic sleep — a schedule involving multiple sh

Cohance Lifesciences hits 20% upper circuit: Why the stock rising today?

Cohance Lifesciences jumped 20% after appointing former Cipla CEO Umang Vohra. Investors are betting his leadership can accelerate growth and transform the comp

30 students suspended at Hansraj College over fest chaos, DUSU calls it undemocratic

Hansraj College has placed around 30 students, including four elected union office-bearers, under interim suspension over alleged misconduct tied to its annual

Decoding the Sun Pharma $11.75 billion deal: Why the pharma stock jumped 7% today?

The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest
spot_img

Related Articles

Popular Categories

spot_imgspot_img